Unique ID issued by UMIN | UMIN000048760 |
---|---|
Receipt number | R000055549 |
Scientific Title | Phase II trial of preoperative chemoradiotherapy using intensity-modulated radiotherapy for locally advanced rectal cancer |
Date of disclosure of the study information | 2022/08/26 |
Last modified on | 2023/02/25 13:57:12 |
Phase II trial of preoperative chemoradiotherapy using intensity-modulated radiotherapy for locally advanced rectal cancer
Phase II trial of preoperative chemoradiotherapy using intensity-modulated radiotherapy for locally advanced rectal cancer
Phase II trial of preoperative chemoradiotherapy using intensity-modulated radiotherapy for locally advanced rectal cancer
Phase II trial of preoperative chemoradiotherapy using intensity-modulated radiotherapy for locally advanced rectal cancer
Japan |
Locally advanced rectal cancer
Gastroenterology | Hematology and clinical oncology | Gastrointestinal surgery |
Radiology |
Malignancy
NO
To explore whether IMRT reduces the acute grade 2 diarrhea in preoperative chemoradiotherapy for locally advanced rectal cancer.
Efficacy
Grade 2 Acute diarrhea
Interventional
Single arm
Non-randomized
Open -no one is blinded
Historical
1
Treatment
Maneuver |
Intensity-modulated radiotherapy (1.8 Gy/fr, 45-50.4Gy), Capecitabine 1650 mg/m2/day oral administration on the day of radiotherapy.
20 | years-old | <= |
Not applicable |
Male and Female
1) Histologically confirmed rectal adenocarcinoma
2) Following three criteria was met,
i) Palpable by digital examination or within 12 cm from anal verge
ii) Positive circumferential resection margin or clinical T3-4N0 or T1-4N1-2
iii) No peritoneal, hepatic and lung metastasis
3) >=20 years old
4) Performance Status 0-2
5) No history of pelvic radiotherapy
6) Adequate organ function
Neutrophil count >= 1500/mm3
Platelet count >=100 000/mm3
Total bilirubin <=1.5 ULN
Both serum aspartate aminotransferase and alanine aminotransferase <=100 IU/L
CCr >= 30 ml/min/body
7) Able to intake orally
8) Grade 0-1 diarrhea
9) Written consent to participate in the current trial
1) Uncontrollable comorbidity (diarrhea, interstitial pneumonia, collagen vascular disease,diabetes mellitus, heart failure etc)
2) Pregnant or child-bearing potential, lactating patients
3) History of hypersensitivity to capecitabine or 5-fluorouracil
4) Currently taking tegafur/Gimeracil/Oteracil or within 7 days after discontinuation
5) Considered to be difficult to participate the current trial from psychotic disorders
55
1st name | Takashi |
Middle name | |
Last name | Mizowaki |
Kyoto University Graduate School and Faculty of Medicine
Department of Radiation Oncology and Image-applied Therapy
6068507
54, Shogoinn, Sakyo-ku,Kyoto, Kyoto
0757513762
mizo@kuhp.kyoto-u.ac.jp
1st name | Katsuyuki |
Middle name | |
Last name | Sakanaka |
Kyoto University Graduate School and Faculty of Medicine
Department of Radiation Oncology and Image-applied Therapy
6068507
54, Shogoinn, Sakyo-ku,Kyoto, Kyoto
0757513762
sakanaka@kuhp.kyoto-u.ac.jp
Kyoto University Hospital
Ministry of Education, Culture, Sports, Science and Technology
Japanese Governmental office
Kyoto University Graduate School and Faculty of Medicine, Ethics Committee
Yoshida-Konoe-cho, Sakyo-ku, Kyoto 606-8501, JAPAN
075-753-4680
ethcom@kuhp.kyoto-u.ac.jp
NO
2022 | Year | 08 | Month | 26 | Day |
Unpublished
Open public recruiting
2022 | Year | 08 | Month | 25 | Day |
2022 | Year | 10 | Month | 17 | Day |
2022 | Year | 10 | Month | 25 | Day |
2026 | Year | 04 | Month | 24 | Day |
2022 | Year | 08 | Month | 25 | Day |
2023 | Year | 02 | Month | 25 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000055549
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |